Shots:

• The submission is based on the P-II study to evaluate the efficacy and safety of valemetostat (200mg, qd)) as monothx. in 25 patients with r/r ATL prior treated with mogamulizumab or at least one systemic CT in case of intolerance/ contraindication for mogamulizumab
• The 1EPs is ORR as assessed by independent efficacy assessment committee & 2EPs include investigator-assessed ORR, best response in tumor lesions, CRR, TCR, time to response, DoR, PFS, OS & safety
• Valemetostat is a dual inhibitor of EZH1 and EZH2 & is currently in clinical development in the Alpha portfolio of Daiichi Sankyo. The therapy has received ODD from the MHLW for r/r ATL

Ref: Businesswire | Image: Daiichi Sankyo